Global Biosimilar and Biologics Supply, Demand and Key Producers, 2024-2030

Global Biosimilar and Biologics Supply, Demand and Key Producers, 2024-2030

The global Biosimilar and Biologics market size is expected to reach $ million by 2030, rising at a market growth of % CAGR during the forecast period (2024-2030).

This report studies the global Biosimilar and Biologics production, demand, key manufacturers, and key regions.

This report is a detailed and comprehensive analysis of the world market for Biosimilar and Biologics, and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2023 as the base year. This report explores demand trends and competition, as well as details the characteristics of Biosimilar and Biologics that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Biosimilar and Biologics total production and demand, 2019-2030, (K Units)

Global Biosimilar and Biologics total production value, 2019-2030, (USD Million)

Global Biosimilar and Biologics production by region & country, production, value, CAGR, 2019-2030, (USD Million) & (K Units)

Global Biosimilar and Biologics consumption by region & country, CAGR, 2019-2030 & (K Units)

U.S. VS China: Biosimilar and Biologics domestic production, consumption, key domestic manufacturers and share

Global Biosimilar and Biologics production by manufacturer, production, price, value and market share 2019-2024, (USD Million) & (K Units)

Global Biosimilar and Biologics production by Type, production, value, CAGR, 2019-2030, (USD Million) & (K Units)

Global Biosimilar and Biologics production by Application production, value, CAGR, 2019-2030, (USD Million) & (K Units).

This reports profiles key players in the global Biosimilar and Biologics market based on the following parameters – company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Roche AG, AbbVie, Novartis AG, Merck, Bristol Myers Squibb, GSK, AstraZeneca and Eli Lilly, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Biosimilar and Biologics market.

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (K Units) and average price (US$/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2019-2030 by year with 2023 as the base year, 2024 as the estimate year, and 2025-2030 as the forecast year.

Global Biosimilar and Biologics Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World

Global Biosimilar and Biologics Market, Segmentation by Type
Monoclonal Antibody
Vaccines
Recombinant Insulin
Growth Factors
Immune Modulators
Fusion Protein
Erythoprotein
Other

Global Biosimilar and Biologics Market, Segmentation by Application
Autoimmune Diseases
Infectious Diseases
Cardiovascular Disorders
Other

Companies Profiled:
Pfizer
Roche AG
AbbVie
Novartis AG
Merck
Bristol Myers Squibb
GSK
AstraZeneca
Eli Lilly
Bayer
Gilead Sciences
Amgen
Boehringer Ingelheim
Novo Nordisk
Viatris
Johnson
Sanofi Winthrop Industries
Serum Institute of India
Biocon
Intas Pharmaceuticals

Key Questions Answered

1. How big is the global Biosimilar and Biologics market?

2. What is the demand of the global Biosimilar and Biologics market?

3. What is the year over year growth of the global Biosimilar and Biologics market?

4. What is the production and production value of the global Biosimilar and Biologics market?

5. Who are the key producers in the global Biosimilar and Biologics market?